Navigate the OncoGenex OGXI research pages
Introduction (Financials, pipeline, milestones, catalysts, general info and links)
Custirsen aka OGX-011 (phase 3 asset for prostate and lung cancer partnered with TEVA, antisense targeting clusterin)
OGX-427 (phase 2 prostate and bladder cancer asset, unpartnered, antisense targeting HSP27)
Early pipeline products (all preclinical and focused on addressing mechanisms of cancer treatment resistance)
Custirsen aka OGX-011 (phase 3 asset for prostate and lung cancer partnered with TEVA, antisense targeting clusterin)
OGX-427 (phase 2 prostate and bladder cancer asset, unpartnered, antisense targeting HSP27)
Early pipeline products (all preclinical and focused on addressing mechanisms of cancer treatment resistance)
OncoGeneX (OGXI)Website link: www.oncogenex.com
Recent Updates: Blue font indicates premium content for Chimera Research Group subscribers Needham webcasts 2/14/11 and 4/6/11 - click for notes (need to incorporate above into stock research page) 1q11 results 5/9/11 - click for PR - click for CC notes 2q11 results 8/4/11 - click here for my notes 8/17/11 Wedbush webcast - click here for notes. 9/7/11 Stifel Nicolaus webcast - click for notes. 9/13/11 Rodman and Renshaw - click for notes. 9/20/11 UBS webcast - click for notes. 11/3/11 3q2011 results CC - click for notes. 2/2012 BIO CEO conference - click for notes. 2/2012 Leerink Swann conference - click for notes. 3/2012 Citi Healthcare conference - click for notes. 3/2012 Cowen Healthcare conference - click for notes. 4/2012 Needham Healthcare conference - click for notes. 5/2012 ASCO preview and partner updates - click for blog. 5/2012 ASCO abstract - click for blog. 6/2012 Comments on new custirsen NSCLC trial [link] 8/2012 Notes from partner TEVA 2q-2012 CC - blog. Links
|
Focused on therapeutics that address mechanisms of treatment resistance in cancer
|
General and Outlook
- Formed 8/2008 via reverse takeover of Sonus Pharmaceuticals
- "Our product candidates custirsen, OGX-427 and OGX-225 focus on mechanisms for treating resistance in cancer patients and are designed to address resistance by blocking the production of specific proteins that we believe promote survival of tumor cells and are over-produced in response to a variety of cancer treatments. Our aim in targeting these particular proteins is to disable the tumor cell’s adaptive defenses, thereby rendering the tumor cell more susceptible to attack with a variety of cancer therapies, including chemotherapy. We believe this approach will increase the time of survival and improve the quality of life for cancer patients." (2010 10k)
- Click here to download 81x slide deck from ASCO 2010 Key Opinion Leader panel - great reference
- Cash into 2014, including: completing SATURN and SYNERGY trials, completing enrollment in NSCLC trial, completing the two ongoing OGX-427 phase 2 trials.
- Needham 4/2011: Cash into 2014, use $31-35m cash in 2011, $50-54m cash ye2011
- Needham 4/2011: does not sound like either CRPC trial will complete enrollment in 2011
- As of 12/31/2010, ISIS does not own any stock in OGXI (all sold during 2009)
- No internal discovery operations. 27 employees (17 in R&D) as of 12/31/10. R&D expenses were $18.5m in 2010
- 10/2010: Sold 3.17m shares for $15.75 (plus 0.5 warrants at $20 expiring 10/2015) for net proceeds of $46.7m
Management
- Scott Cormack - Chief Executive Officer (CEO)
- Michelle Burris - Chief Financial Officer (CFO)
- Cindy Jacobs - Chief Medical Officer (CMO)